Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)

详细信息    查看全文

• 作者：Wen-Hsing Lin^&dagger ; ; John T.-A. Hsu^&dagger ; ; Shu-Yi Hsieh^&dagger ; ; Chiung-Tong Chen ; Jen-Shin Song ; Shih-Chieh Yen ; Tsu Hsu ; Cheng-Tai Lu ; Chun-Hwa Chen ; Ling-Hui Chou ; Yung-Ning Yang ; Ching-Hui Chiu ; Ching-Ping Chen ; Ya-Ju Tseng ; Kuei-Jung Yen ; Ching-Fang Yeh ; Yu-Sheng Chao ; Teng-Kuang Yeh ; Weir-Torn Jiaang ; ^{wtjiaang@nhri.org.tw}
• 关键词：FMS-like tyrosine kinase-3 ; Inhibitor ; Acute myeloid leukemia ; Receptor tyrosine kinase ; Internal tandem duplications
• 刊名：Bioorganic and Medicinal Chemistry
• 出版年：2013
• 出版时间：1 June, 2013
• 年：2013
• 卷：21
• 期：11
• 页码：2856-2867
• 全文大小：1981 K

文摘

Preclinical investigations and early clinical trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia. However, early clinical data have been underwhelming due to incomplete inhibition of FLT3. We have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors. Structure-activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors. Previous studies showed that the sulfonamide 4 and carbamate 5 series were potent and selective FLT3 inhibitors with good in vivo efficacy. Herein, we describe the urea series, which we found to be potent inhibitors of FLT3 and VEGFR2. Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib (2) and ABT-869 (3). In preliminary in vivo toxicity studies of the four most active compounds, 10f was found to be the least toxic. A further in vivo efficacy study demonstrated that 10f achieved complete tumor regression in a higher proportion of MOLM-13 xenograft mice than 4 and 5 (70 % vs 10 % and 40 % ). These results show that compound 10f possesses improved pharmacologic and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia.